Richard Gonzalez, AbbVie CEO (Chris Kleponis via AP Images)

Ab­b­Vie adds de­pres­sion in­di­ca­tion to Vray­lar's la­bel months af­ter Gon­za­lez touts $4B+ peak sales po­ten­tial

Ab­b­Vie CEO Richard Gon­za­lez wants to bring Vray­lar to new heights. On Fri­day, reg­u­la­tors set the next phase of his plan in mo­tion.

The FDA ap­proved Vray­lar, al­so known as cariprazine, as an add-on ther­a­py for adults with ma­jor de­pres­sive dis­or­der (MDD), one of the most com­mon men­tal dis­or­ders in the US. That marks Vray­lar’s fourth in­di­ca­tion be­hind schiz­o­phre­nia, the acute treat­ment of man­ic or mixed episodes in those with bipo­lar I dis­or­der, and de­pres­sive episodes in bipo­lar I pa­tients.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.